文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19患者肺移植

Lung Transplantation for Patients With COVID-19.
PubMed 文献 · Chest · 2021-08-19
一句话结论综述:COVID-19相关ARDS或感染后肺纤维化少数患者可成功肺移植,但需权衡独特挑战与自然恢复不确定性。

本文综述了COVID-19相关急性呼吸窘迫综合征(CARDS)及感染后肺纤维化患者肺移植的适应证与挑战。全球有限病例中肺移植已成功用于CARDS和感染后肺纤维化。CARDS患者面临无法进行心理社会评估和移植前教育、危重病导致严重去适应及病毒再激活感染风险;感染后肺纤维化患者则因对COVID-19后自然恢复病程知识有限而决策困难。移植医生需权衡风险获益,尤其对可能稳定或逐渐改善者与已知进展性纤维化间质性肺病(fILD)患者不同。

要点

  • CARDS患者无法脱离机械通气或感染后肺纤维化需长期补氧时,治疗团队常询问肺移植可能性。
  • 全球有限病例中,肺移植已成功用于CARDS和感染后肺纤维化。
  • CARDS患者移植前主要障碍:无法进行心理社会评估和移植前教育、危重病去适应、病毒再激活感染风险。
  • 感染后肺纤维化患者决策难点:对COVID-19急性肺损伤后恢复可能性和程度知识有限。
  • 移植医生需区别对待可能稳定或逐渐改善的感染后肺纤维化患者与已知进展性fILD患者。

适用人群与场景

  • COVID-19相关急性呼吸窘迫综合征(CARDS)无法脱离机械通气的患者。
  • COVID-19感染后肺纤维化导致显著残疾和需要长期补充氧疗的患者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 综述:全球有限病例中肺移植已成功用于CARDS和感染后肺纤维化。
  • CARDS患者移植挑战包括无法进行心理社会评估和移植前教育、危重病去适应、病毒再激活感染风险。
  • 感染后肺纤维化患者挑战为对COVID-19后自然恢复病程知识有限。
  • 移植医生需权衡可能稳定或逐渐改善的感染后肺纤维化患者与已知进展性fILD患者的不同风险获益。

证据类型、等级与局限

  • 综述,来自多个有经验中心的肺移植提供者经验讨论。
  • 局限:基于有限病例和有限知识,原文未提供系统评价或证据等级。

对床旁实践的改变

  • 对CARDS无法脱机或感染后肺纤维化需长期补氧者,可考虑肺移植评估。
  • CARDS患者移植前需面对心理社会评估受限、去适应和病毒再激活风险。
  • 感染后肺纤维化患者决策需考虑自然恢复不确定性,与进展性fILD区别对待。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

The COVID-19 pandemic has caused acute lung injury in millions of individuals worldwide. Some patients develop COVID-related acute respiratory distress syndrome (CARDS) and cannot be liberated from mechanical ventilation. Others may develop post-COVID fibrosis, resulting in substantial disability and need for long-term supplemental oxygen. In both of these situations, treatment teams often inquire about the possibility of lung transplantation. In fact, lung transplantation has been successfully employed for both CARDS and post-COVID fibrosis in a limited number of patients worldwide. Lung transplantation after COVID infection presents a number of unique challenges that transplant programs must consider. In those with severe CARDS, the inability to conduct proper psychosocial evaluation and pretransplantation education, marked deconditioning from critical illness, and infectious concerns regarding viral reactivation are major hurdles. In those with post-COVID fibrosis, our limited knowledge about the natural history of recovery after COVID-19 infection is problematic. Increased knowledge of the likelihood and degree of recovery after COVID-19 acute lung injury is essential for appropriate decision-making with regard to transplantation. Transplant physicians must weigh the risks and benefits of lung transplantation differently in a post-COVID fibrosis patient who is likely to remain stable or gradually improve in comparison with a patient with a known progressive fibrosing interstitial lung disease (fILD). Clearly lung transplantation can be a life-saving therapeutic option for some patients with severe lung injury from COVID-19 infection. In this review, we discuss how lung transplant providers from a number of experienced centers approach lung transplantation for CARDS or post-COVID fibrosis.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. King CS, Mannem H, Kukreja J, et al. Lung Transplantation for Patients With COVID-19. Chest. 2021. PMID: 34418410. doi:10.1016/j.chest.2021.08.041

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。